12:00 AM
Dec 17, 2012
 |  BC Week In Review  |  Clinical News  |  Regulatory

Brintellix vortioxetine regulatory update

H. Lundbeck and partner Takeda said FDA accepted for review an NDA for Brintellix vortioxetine to treat major depressive disorder (MDD). The PDUFA...

Read the full 91 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >